Onxeo: Disclosure of Total Number of Voting Rights and

PARIS--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory News:

Pursuant to article L.233-8 II of the Code de commerce (the French Commercial
Code) and article 223-16 of the Règlement général de l’Autorité des Marchés
Financiers (Regulation of the French stock market authority):

Date      Total           Total number of voting rights
          number of
          outstanding
          shares
April     40, 544,        Theoretical number of voting rights:
30,       204             40, 544, 204
2015                      (including treasury shares)Number of
                          real voting rights: 40, 518, 878
                          (without
                          treasury shares)

About Onxeo
Onxeo (Paris:ONXEO) (NASDAQ OMX:ONXEO) has the vision to become a global leader
and pioneer in oncology, with a focus on orphan or rare cancers, through
developing innovative therapeutic alternatives to “make the difference”. The
Onxeo teams are determined to develop innovative medicines to provide patients
with hope and significantly improve their lives.

Key products at advanced development stage are:
Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
Validive® (Clonidine Lauriad®): Positive preliminary results of the Phase II
trial in severe oral mucositis
Beleodaq® (belinostat): registered in the US in peripheral T-cell lymphoma
For more information, visit the
website www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3
A 
%2F%2Fwww.onxeo.com&esheet=51106972&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=1&md5=4bd617a117e29237e2c300f8568c0971)
Contacts:

Onxeo
Judith Greciet, CEO
j.greciet@onxeo.com
Nicolas Fellmann, CFO
n.fellmann@onxeo.com
+33 1 45 58 76 00
or
Caroline Carmagnol, Alize RP
onxeo@alizerp.com
+33 6 64 18 99 59 / +33 1 44 54 36 62
Onxeo: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at April 30, 2015

Attachments
